Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Infasurf Generic Name & Formulations
Legal Class
Rx
General Description
Calfactant (as phospholipids 35mg/mL and 0.65mg proteins/mL); susp for intratracheal administration; preservative-free.
Pharmacological Class
Lung surfactant.
How Supplied
Single-use vials (6mL)—1
Manufacturer
Infasurf Indications
Indications
Prevention and treatment of respiratory distress syndrome (RDS) in premature infants.
Infasurf Dosage and Administration
Adult
Not applicable.
Children
See literature. Give by intratracheal administration through an endotracheal tube. 3mL/kg birth weight per dose (as 2 aliquots of 1.5mL/kg each) every 12 hours for 3 doses.
Infasurf Contraindications
Not Applicable
Infasurf Boxed Warnings
Not Applicable
Infasurf Warnings/Precautions
Warnings/Precautions
Interrupt dosing if reflux of product into endotracheal tube, cyanosis, bradycardia, airway obstruction, hypoventilation, or endotracheal tube dislodgement occurs; treat; resume after stabilization. Monitor respiratory status and clinical condition frequently and carefully.
Infasurf Pharmacokinetics
See Literature
Infasurf Interactions
Not Applicable
Infasurf Adverse Reactions
Adverse Reactions
Cyanosis, airway obstruction, bradycardia, reflux of surfactant into endotracheal tube, requirement for mechanical ventilation, reintubation, others.
Infasurf Clinical Trials
See Literature
Infasurf Note
Not Applicable
Infasurf Patient Counseling
See Literature
